Skip to content

Virtual Reality (VR) Audiovisual Distraction to Reduce Pain and Anxiety for Prone Pain Procedures

Virtual Reality (VR) Audiovisual Distraction to Reduce Pain and Anxiety for Prone Pain Procedures

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07779083
Enrollment
230
Registered
2026-08-21
Start date
2026-10-01
Completion date
2028-12-01
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural Anxiety, Procedural Pain

Keywords

Virtual Reality, Pain, Anxiety, Prone Pain Procedure, Audiovisual Distraction

Brief summary

This study evaluates whether virtual reality (VR) audiovisual distraction can reduce pain, anxiety, and the need for pain and anxiety medications during prone pain procedures, compared to standard care alone. The trial design is a two-arm, parallel assignment, randomized controlled trial at a single site, the UC Davis Pain Medicine Clinic. Patients will be randomized in a 1:1 allocation to the intervention (commercially available virtual reality headset (Meta Quest 3) with audiovisual calming nature scene and an ergonomic cushion/support) vs control (standard medical care). The primary outcome will be a composite outcome analyzed using the Win Ratio method comparing opioid/sedative medication use, intra-procedural pain scores, and intra-procedural anxiety scores between groups. Approximately 230 people at UC Davis are expected to participate (Up to 20 patients for the preliminary run-in period to acclimatize research and clinical staff and 210 total for the randomized clinical trial). Each participant's involvement consists of one visit, estimated at 30 minutes.

Interventions

BEHAVIORALVirtual Reality (VR) Audiovisual Distraction

Using a VR headset with an ergonomic cushion/support which will display a calming audiovisual experience during the procedure. The VR headset is a commercially available Meta Quest 3.

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

N/A - The nature of the VR intervention (wearing a headset) prevents blinding of participants and care providers.

Intervention model description

Two-arm, parallel assignment, randomized controlled trial. Patients will be randomized in a 1:1 allocation to the intervention (VR headset with audiovisual calming nature scene and ergonomic cushion/support) vs control (standard medical care).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years old or older * Male and female gender * Referred to UC Davis Pain Medicine Clinic and require a prone pain procedure * English speaking and with the ability to understand oral and written instructions

Exclusion criteria

* Pregnant women * Prisoners * Patients who have high risk of motion sickness * Seizure disorder * Visual/hearing impairment

Design outcomes

Primary

MeasureTime frameDescription
Composite Outcome Using Win Ratio Method (Opioid/Sedative Use, Intra-procedural Pain Score, and Intra-procedural Anxiety Score)During the procedure, approximately 30 minutesThe primary outcome is a composite analyzed using the Win Ratio method. Each intervention patient will be compared with each control patient. Pairs are evaluated in priority order: opioid/sedative use, intra-procedural pain score, then intra-procedural anxiety score. A patient who received no opioids/sedatives wins over one who did; if tied, the lower pain score wins; if still tied, the lower anxiety score wins. If all three measures are identical, the pair is a tie. The Win Ratio is calculated as total intervention wins divided by total control wins. A Win Ratio \>1 indicates superiority of VR; a 95% confidence interval will be calculated. Pain and anxiety are measured using the Numeric Rating Scale (NRS), from 0 (none) to 10 (worst possible), with higher scores indicating worse outcomes.

Secondary

MeasureTime frameDescription
Opioid and Sedative Medication UseDuring the procedure, approximately 30 minutesWhether opioid and/or sedative medications were administered during the prone pain procedure.
Intra-procedural Pain Score on the Numeric Rating Scale (NRS)During the procedure, approximately 30 minutesPain assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst possible pain). Higher scores indicate a worse outcome.
Intra-procedural Anxiety Score on the Numeric Rating Scale (NRS)During the procedure, approximately 30 minutesAnxiety assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no anxiety) to 10 (worst possible anxiety). Higher scores indicate a worse outcome.
Pain Intensity on the Patient-Reported Outcomes Measurement Information System Pain Intensity Short Form-3a (PROMIS Pain Intensity SF-3a)Pre-procedure and post-procedure, approximately 30 minutesPROMIS Pain Intensity Short Form-3a. Scores range from 3 to 15. Higher scores indicate a worse outcome.
Anxiety on the State-Trait Anxiety Inventory 6-item (STAI-6)Pre-procedure and post-procedure, approximately 30 minutesState-Trait Anxiety Inventory 6-item (STAI-6). Scores range from 4 to 24. Higher scores indicate a worse outcome.
Patient Global Impression of Change (PGIC)Post-procedure, approximately 30 minutesPatient Global Impression of Change. Scores range from 1 to 7. Higher scores indicate a better outcome.
Patient Experience SatisfactionPost-procedure, approximately 30 minutesPatient Experience Satisfaction. Scores range from 0 to 10. Higher scores indicate a better outcome.
Virtual Reality Experience FeedbackPost-procedure, approximately 30 minutesVirtual Reality experience feedback (immersion, comfort, side effects, usability, task load). No score range or directionality as it is a free response section.

Countries

United States

Contacts

CONTACTMichael J. Jung, MD, MBA
mijjung@health.ucdavis.edu916-734-6824
PRINCIPAL_INVESTIGATORMichael J. Jung, MD, MBA

University of California, Davis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026